Publicaciones en colaboración con investigadores/as de Hospital Universitario San Cecilio (25)

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Mucosal Immune Defence Gene Polymorphisms as Relevant Players in the Pathogenesis of IgA Vasculitis?

    International Journal of Molecular Sciences, Vol. 24, Núm. 17

2022

  1. RICORS2040: The need for collaborative research in chronic kidney disease

    Clinical Kidney Journal, Vol. 15, Núm. 3, pp. 372-387

2021

  1. Author Correction: BAFF, APRIL and BAFFR on the pathogenesis of Immunoglobulin-A vasculitis (Scientific Reports, (2021), 11, 1, (11510), 10.1038/s41598-021-91055-z)

    Scientific Reports

  2. BAFF, APRIL and BAFFR on the pathogenesis of Immunoglobulin-A vasculitis

    Scientific Reports, Vol. 11, Núm. 1

  3. Role of the IL33 and IL1RL1 pathway in the pathogenesis of Immunoglobulin A vasculitis

    Scientific Reports, Vol. 11, Núm. 1

2020

  1. The value of the continuous genotyping of multi-drug resistant tuberculosis over 20 years in Spain

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. Identification of a 3′-Untranslated Genetic Variant of RARB Associated With Carotid Intima-Media Thickness in Rheumatoid Arthritis: A Genome-Wide Association Study

    Arthritis and Rheumatology, Vol. 71, Núm. 3, pp. 351-360

  2. Spanish Registry of Recent-onset Psoriatic Arthritis (REAPSER study): Aims and methodology

    Reumatologia Clinica, Vol. 15, Núm. 5, pp. 252-257

2017

  1. A combined large-scale meta-Analysis identifies COG6 as a novel shared risk locus for rheumatoid arthritis and systemic lupus erythematosus

    Annals of the Rheumatic Diseases, Vol. 76, Núm. 1, pp. 286-294

  2. Interferon-related genetic markers of necroinflammatory activity in chronic hepatitis C

    PLoS ONE, Vol. 12, Núm. 7

2016

  1. Infection is the major trigger of hemophagocytic syndrome in adult patients treated with biological therapies

    Seminars in Arthritis and Rheumatism, Vol. 45, Núm. 4, pp. 391-399

  2. Off-label use of rituximab for systemic lupus erythematosus in Europe

    Lupus Science and Medicine, Vol. 3, Núm. 1

2015

  1. Registry of the Spanish network for systemic sclerosis: Survival, prognostic factors, and causes of death

    Medicine (United States), Vol. 94, Núm. 43

2014

  1. Analysis of ancestral and functionally relevant CD variants in systemic lupus erythematosus patients

    PLoS ONE, Vol. 9, Núm. 11

  2. Influence of the IL17A locus in giant cell arteritis susceptibility

    Annals of the Rheumatic Diseases, Vol. 73, Núm. 9, pp. 1742-1745

2012

  1. The undiagnosed cases of Clostridium difficile infection in a whole nation: Where is the problem?

    Clinical Microbiology and Infection, Vol. 18, Núm. 7

2011

  1. Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label

    Arthritis Research and Therapy, Vol. 13, Núm. 4

2010

  1. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases

    Clinical and Experimental Rheumatology, Vol. 28, Núm. 4, pp. 468-476

2009

  1. No evidence for genetic association of interferon regulatory factor 3 in systemic lupus erythematosus

    Lupus, Vol. 18, Núm. 3, pp. 230-234